Processa Pharmaceuticals, Inc. (PCSA) is approaching a closely watched clinical milestone as the company prepares to deliver interim results from its Phase 2 NGC-Cap study in advanced or metastatic breast cancer.
The update, expected in the first quarter of 2026, follows the company's January 5, 2026, announcement that it had completed enrolment and dosing of the first 20 patients required for the formal interim analysis. The study evaluates NGC-Cap - a combination of PCS6422 and Capecitabine - in patients who have already undergone multiple prior cancer treatments.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com